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Abstract
The methodology to create induced pluripotent stem cells (iPSCs) affords the opportunity to generate cells specific to the
individual providing the host tissue. However, existing methods of reprogramming as well as the types of source tissue have
significant limitations that preclude the ability to generate iPSCs in a scalable manner from a readily available tissue source.
We present the first study whereby iPSCs are derived in parallel from multiple donors using episomal, non-integrating, oriP/
EBNA1-based plasmids from freshly drawn blood. Specifically, successful reprogramming was demonstrated from a single
vial of blood or less using cells expressing the early lineage marker CD34 as well as from unpurified peripheral blood
mononuclear cells. From these experiments, we also show that proliferation and cell identity play a role in the number of
iPSCs per input cell number. Resulting iPSCs were further characterized and deemed free of transfected DNA, integrated
transgene DNA, and lack detectable gene rearrangements such as those within the immunoglobulin heavy chain and T cell
receptor loci of more differentiated cell types. Furthermore, additional improvements were made to incorporate completely
defined media and matrices in an effort to facilitate a scalable transition for the production of clinic-grade iPSCs.
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Introduction
Fibroblasts have been a predominate source material for the
development of the process to generate induced pluripotent stem
cells (iPSCs) given their ability to expand, endure for multiple
passages inculture,andreceptiveness toefficientinfection byviruses
expressing a combination of transcription factors for reprogram-
ming [1–6].However, fibroblasts from skin biopsies require invasive
surgical procedures, are labor intensive and isolating a sufficient
number for reprogramming takes time. In addition, the ability to
generate iPSCs from skin appears inversely correlated with the age
of the donor likely due to increasing exposure to external mutagens
[7]. There is value, therefore, in alternative tissue sources to
generate iPSCs that minimize the risk for additional mutation,
involve less invasive procedures, and are amenable to industriali-
zation to increase availability across an extensive population range.
A blood draw is an ideal starting point to generate donor-specific
iPSCs because it is minimally invasive and established procedures
are already in place for acquisition and handling [8]. Lymphocytes
comprise a large fraction of the peripheral blood mononuclear cell
(PBMC) population but pose at least two potential limitations. First,
they are subject to intrinsic DNA rearrangements such as those that
occur in B and T cells at the V, D, and J gene segments as well as T
cell receptor (TCR) loci to generate a diverse repertoire of antigen-
specific surface immunoglobulins. These rearrangements are
subsequently perpetuated in iPSCs generated from them and their
impactoniPSCfunctioniscurrentlyunknown[9,10].Second,some
research has indicated that host cell types may influence functional
properties of iPSCs [11,12]. For example, while embryonic stem
(ES) cells and progenitor cells derived from bone marrow
successfully differentiate into B cells, iPSCs derived from B cells
have demonstrated resistance to this ability [13,14,15]. Therefore,
choosing an early lineage cell type that lacks DNA rearrangements
alleviates the potential risk of reduced ability to differentiate.
Somatic cells that are characteristically more progenitor-like
with respect to the expression of early lineage markers, such as
CD34, appear more susceptible to reprogramming, and they too
can be isolated from blood [16]. For example, Haase and
colleagues successfully isolated and reprogrammed early progen-
itor cells isolated from cord blood. The ability to reprogram cells
from peripheral blood, however, expands the range of host cells
available for reprogramming especially when acquisition of cord
blood-derived material is not an option. However, the amount of
CD34+ cells represents less than 0.1% of the population of
PBMCs thus limiting the amount of source material available for
reprogramming. To generate enough starting material to perform
reprogramming trials, Loh and colleagues relied on patients
treated with granulocyte-colony stimulating factor (G-CSF) to
expand the number of CD34+ cells in circulating peripheral blood
and ultimately generated iPSCs from these cells [17]. The
acquisition of blood that does not require donors to receive these
agents would be more desirable to avoid the negative side effects
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mobilized blood demonstrate functional differences when com-
pared with cells from non-mobilized samples indicating changes to
properties intrinsic to the cell [19]. For example, epigenetic and
genetic anomalies (i.e. aneuploidy) have been detected in cells
derived from patients mobilized with G-CSF [20,21]. These
observations increase the likelihood that similar genetic modifica-
tions would carry over into iPSCs generated from mobilized
CD34+ cells and potentially impact their function.
The method to generate iPSCs from cord and mobilized peripheral
blood has predominately relied on viral-based methods to introduce
reprogramming factors [16,17]. Resulting clones thus have transgenes
integrated into their genomes that may alter the function of iPSCs,
increase the risk of cancer, and hinder their potential for clinical
application. Improvements to reprogramming methods have been
made to eliminate integrated transgenes including a recent study
examining the reprogramming potential of blood-derived cells using a
previously described episomal, oriP/EBNA1-based transfection
method [2,22,23]. We capitalized on the oriP/EBNA1-method but
made modifications to accommodate the reprogramming of CD34+
cells derived from actual vials of blood collected across multiple
donors. The oriP/EBNA1-based vectors contribute to the replication
and retention of plasmids during each cell division long enough for
reprogramming to occur and are lost over time resulting in cells free of
transfected DNA and integrated transgenes [24,25]. Importantly,
reprogramming can be achieved through a single transfection. Herein
we demonstrate the ability to generate iPSCs from a single vial of
blood or less using an improved process of reprogramming that
incorporates fully defined conditions to generate iPSCs free of gene
rearrangements and transgene elements.
Results
Hematopoietic progenitor cells from non-mobilized,
peripheral blood are expandable
Hematopoietic progenitor cells expressing CD34 represent a
small fraction of the population and limit the number of cells
available for reprogramming; therefore, a modified formulation of
a media used to expand cord blood cells was tested on CD34+ cells
isolated from peripheral blood [26]. CD34+ cells from two non-
mobilized, peripheral (PB.1 and PB.2) blood donors were tested in
comparison to CD34+ cells from two cord blood donors (CB.1 and
CB.2). Cells were placed into untreated, 24-well culture plates at
1.2610
4 per ml of expansion media (StemSpan basal medium;
300 ng/ml each of SCF, Flt3, TPO; 100 ng/ml IL-6; 10 ng.ml
IL-3) and fed 3 to 4 days later. The total number of cells from
peripheral blood expanded 170-fold and 680-fold from cord blood
after 10 to 14 days in culture (Figure 1A, left hand panel). The
percentage of CD34+ cells in the peripheral and cord blood
samples peaked in less than 1 week (CB data not shown; Figure 1A,
right hand panel). The expression profile of expanding populations
was determined by flow cytometry for all donors examined herein
(Figure 1B). Phenotypic analysis of the resulting peripheral blood
culture PB.2 after 10 days of expansion revealed predominately
early progenitor cells expressing CD43, CD45, CD33, CD44,
CD15, and CD117 and marginal levels of T (CD3, CD4, CD8),
NK (CD56, CD94), B (CD19), macrophage (CD163), megakar-
yocyte (CD41), and monocyte (CD14) cells (Figure 1C).
These expansion conditions were then applied to cells acquired
from a single vial of blood collected from multiple donors. PBMCs
were isolated, frozen down immediately, or directly purified for
CD34+ cells and seeded for expansion. On average, 1610
7 PBMCs
were recovered per 8 ml vial of blood and yielded approximately
2610
4 cells after purification for CD34-expressing cells (data not
shown). Although the magnitude of expansion was variable, cells
from all of the donors demonstrated expansion ranging from 3 to
83-fold after 6 days in culture and approximately 48+/219% of
that population expressed CD34 (Figure 1D).
Optimizing the generation of iPSCs with small molecules
and a defined matrix
The total number of purified cells isolated from a single, 8 ml vial
of blood can be as little as 2610
4 CD34+ cells; therefore, a range of
CD34+ cell numbers was tested to determine transfection efficiency
from low cell numbers. The efficiency of transfection was
determined by transfecting an oriP/EBNA1-containing plasmid
encoding GFP into expanded CD34+ cells and assessing them by
flow cytometry. Viability was determined by identifying the fraction
of viable cells that did not stain positively for trypan blue the day
aftertransfectiondividedbythetotalnumberofinputcells.Viability
wasapproximately30%when 1610
4 to1610
5input cellswereused
fortransfection(datanotshown).Cell numbers at1610
4 and 3610
4
resulted in an efficiency of 30% and was 40% when using 6610
4
and 1610
5 cells (Figure 2A). Cells expanded for only 3 days
demonstrated a two-fold increase in transfection efficiency. Over
90%ofthosecellsalsoco-expressedGFP and CD34whileonly18%
of the cells transfected after 6 days of expansion co-expressed both
markers (Figure 2B, C). These results support the notion that the
conditions selected for this protocol favor the transfection of CD34+
cells present in the population.
We anticipated variability in reprogramming efficiency given the
differences already observed across donors for other cell types tested
and with other methods of reprogramming. Therefore, we
optimized the matrix, media, and plasmid combinations used for
reprogramming. Firstly, a common source of variation occurs when
MEFs or matrigel are used because both are undefined,
cumbersome to prepare, and vary from lot-to-lot. Therefore, we
established a defined matrix by testing a variety of commercially
available possibilities. Recombinant protein fragments containing
the active domains of human fibronectin (RetroNectin) or
vitronectin consistently supported iPSC formation the best among
those tested. Second, the efficiency of colony formation on
RetroNectin-coated plates improved significantly when used in
combination with StemSpan SFEM media, N2, B27, and a cocktail
of small molecules that included PD0325901, CHIR99021, A-83-
01, and HA-100 (Figure 3A). These molecules have been described
previously as inhibitors of MEK, GSK3b, TGFb, and ROCK
pathways, respectively [27,28]. Patches of adherent cells appeared
within one week and became a positive indicator for progression
into iPSCs since hematopoietic cells are typically cultured in
suspension. The following week many of the colonies exhibited
overt characteristics typical of an iPSC and stained positively for the
common pluripotency markers Tra-1-81 and alkaline phosphatase
(AP) (Figure 3A). The borders of the colonies were compact and the
nucleoli more visible when cultures were transitioned to defined,
TeSR2 media without small molecules 1.5 to 2 weeks following
transfection. Thirdly, episomal oriP/EBNA1-based plasmids were
used to deliver Oct4, Sox2, Klf4, C-myc, Nanog, Lin28, and SV40
Large T-antigen as previously described (Set 1; Figure 3B) [2].
Different combinations of reprogramming plasmids were also tested
to determine whether a boost in reprogramming efficiency was
possible. Based on previous reports indicating the benefit of L-myc
in reprogramming trials, we modified plasmid combination Set 1
and substituted L-myc in place of C-myc (Set 2, Figure 3B) [29,30].
While an improvement was not observed when C-myc was
substituted for L-myc in the combination of plasmids represented
in Set 1 (data not shown), an equal to or two-fold improvement was
observed with plasmid Set 2 expressing L-myc (Figure 3C).
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revealed more consistent generation of iPSCs when transfecting
greater than 5610
4 cells (Figure 3D).
Optimization of iPSCs generated from CD34+ cells
isolated from fresh, whole blood across multiple donors
The next step was to confirm iPSCs could be generated from
actual vials of human blood, ensure cell numbers optimized for
expansion and transfection are applicable across multiple donors,
and determine whether the starting volume of blood can be
minimized. Colonies emerging during reprogramming were
scored positive by their ability to express Tra1-81 and exhibit a
classic embryonic stem (ES) cell-like morphology. After colonies
were picked from the reprogramming cultures, a subset of them
were further characterized to confirm their pluripotency. Repro-
gramming efficiency was calculated in two ways 1) the number of
iPSCs divided by the total volume of blood collected from each
Figure 2. Identifying optimal transfection conditions for CD34+ cells. A. PBMCs (donor GG) were isolated and purified for CD34-expression
and expanded for 6 days. A range of cell numbers were transfected with a control, oriP/EBNA1-based plasmid expressing GFP. Transfection efficiency
was determined by calculating the percentage of viable cells expressing GFP detectable by flow cytometry (n=6). B. PBMCs (donor A2389) were
isolated, purified for CD34-expression and expanded for 3 or 6 days. 6610
4 to 1610
5 cells were transfected with the control, GFP-expressing plasmid.
The graph depicts the percent of the total population that is GFP-positive along with the absolute number of total cells (n=3). C. The graph
represents the fraction of cells in B that co-express GFP and CD34 when transfected at 3 or 6 days of expansion (n=3).
doi:10.1371/journal.pone.0027956.g002
Figure 1. Hematopoietic cells enriched for CD34 expression are expandable. A. Graphs depict the expansion of purified cells from either
two peripheral (PB.1 and PB.2) or cord (CB.1 or CB.2) blood donors over time (lefthand panel) along with the percentages of the total population that
are CD34+ (righthand panel). B. Representative profile of a purified population of cells after 6 days of expansion by flow cytometry on cells isolated
from Donor 3002. Flow cytometry plots from control staining using IgG antibodies (upper plots) are compared to plots with antibodies specific to
lineage markers (lower plots). C. The graph represents an extended analysis by flow cytometry of the characteristic profile of PB.2 cells after 10 dayso f
expansion. The % positive indicates the fraction of the population expressing the cell surface markers on the x-axis. D. The total number of CD34+
cells across 16 different donors was assessed beginning at 0 and 6 days of expansion (left side y-axis). The fold expansion (right side y-axis, orange
squares) was determined by dividing the total number of cells at day 6 divided by the number of cells at day 0 after purification. The average percent
of CD34 expression across all 16 donors was 48+/219%.
doi:10.1371/journal.pone.0027956.g001
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cells for transfection multiplied by 1610
5 cells. The first
calculation incorporates the whole process beginning from the
blood collection to the generation of an iPSC. The second
calculation removes the variability incurred during the isolation of
PBMCs, purification, and expansion and focuses on the number of
iPSCs generated per number of cells placed into transfection.
We tested blood collected across donors spanning a range of
ethnicities, ages, and genders to confirm iPSCs could be generated
from CD34+ cells purified from fresh blood draws (Table 1). Six of
these donors provided up to 55 ml of blood, and PBMCs from
them were either isolated and used directly for purification,
expansion, and reprogramming or frozen down after isolation.
iPSCs were successfully generated from all six donors regardless of
whether they were from fresh or frozen cells despite the lower
efficiency of reprogramming, less than 1 iPSC per ml of blood
(Table 2). Next, smaller volumes of blood representative of a single
vial were obtained from six different donors to test parameters
established in earlier experiments such as the number of cells for
transfection and plasmid combinations. The cell numbers used for
transfection from donors 3052, 3233, and 3373 ranged from
2610
4 to 4610
4 which fall below the minimum, 5610
4 cells,
established with our optimization studies. These experiments
resulted in less than one iPSC per ml of blood (Table 2). Also,
transfections with cells from donors 2583, 2970, and 3185
represent early trials performed with plasmid Set 1 expressing
C-myc before Set 2 plasmids expressing L-myc were fully
optimized which may have resulted in more iPSCs.
The next step was to then extend the insights acquired from
these donors and verify the robustness of our protocol against ten
new donors. The average number of iPSCs per ml of blood and
per 1610
5 cells across these donors indeed improved after
incorporating experience with handling and the testing performed
on the earlier donor samples (Table 3). Furthermore, these
experiments were extended to test even smaller volumes of blood
from a subset of the same donors in Table 3. CD34+ cells purified
from approximately 4 ml of blood were sufficient to generate
iPSCs from all six donors tested, and CD34+ cells from
Figure 3. Plasmid transfections to optimize reprogramming efficiency. A. Representative reprogramming trial from freshly drawn blood
(donor 3002) using combination plasmid Set 2 for transfection. A single well is shown from a 6-well plate that contains colonies staining positively for
AP activity (i). The white arrowhead highlights the colony magnified in panel ii that also stained positively for Tra-1-81 expression (green), panel iii. B.
Schematic of the plasmid sets successfully used for reprogramming trials. Set 1 contains a combination of two plasmids for transfection whereby a
20 kb plasmid that either contains C- or L-myc is depicted. Set 2 includes a three plasmid combination for transfection. C. CD34+ cells purified from
four different donors were expanded for 6 days and transfected using the plasmid combination that expresses either Set 1 or Set 2 plasmid sets to
compare the total number of resulting iPSCs. D. Reprogramming trials were performed using plasmid Set 2 to transfect a range of cell numbers
expanded for 6 days (donor GG, n=6).
doi:10.1371/journal.pone.0027956.g003
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generated iPSCs (Table 4). These results demonstrate that iPSCs
can be generated from CD34+ isolated from tractable volumes of
blood using this non-intergrating and feeder-free method of
reprogramming.
iPSCs derived from peripheral blood are pluripotent and
free of transgene elements
Multiple iPSCs from each of the donors that werereprogrammed
from Tables 2, 3, and 4 were selected for further characterization to
confirm their pluripotency. The clones exhibited a normal
karyotype, were positive for Tra-1-81 and SSEA-4 expression by
flow cytometry as well as endogenous genes DNMT3B, REX1,
TERT, UTF1, Oct4, Sox2, Nanog, Lin28, Klf4, and C-myc
(Table 5, Figure 4A–C). Clones did not exhibit integrated transgene
or episomal elements and loss of episomal DNA occurred, on
average, within 7–10 passages (Table 5, Figure 4D,E). A PCR
screen did not reveal rearrangements pertainingto immunoglobulin
heavy chain (IgH) or a subset of T cell receptor (TCR) gene
segments (Table 5, Figure 4F). The lack of rearrangements supports
the notion that the protocol selectively favors the production of
iPSCs from hematopoietic progenitors rather than more differen-
tiated cell types. When used for in vitro directed differentiation at
passage 15, donor 2939 iPSC clones 4 and 5, which have lost
episomal plasmids, were competent to form neurons (Figure 5G).
Furthermore, five iPS clones from three different donors also
formed teratomas after injection into immunodeficient (SCID) mice
(Figure 4G). Interestingly, the presence of residual episomal
plasmids did not appear to hinder the ability to form teratomas
since clone 6 from donor 2970 did not lose transfected plasmids
until passage 18, well after injection into mice for teratoma studies.
Reprogramming efficiency correlates with the amount of
CD34-expression
The isolation of CD34+ cells from PBMCs creates an additional
step in our process and others have demonstrated successful
reprogramming directly from PBMCs without the need for
purification [22]. Therefore, several experiments to determine
whether a correlation exists between CD34+ cells and reprogram-
ming efficiency were performed. First, the expanding CD34+
populations were screened by flow cytometry for characterization
prior to transfection. T, B, and NK cells were undetectable after 3
and 6 days of expansion demonstrated by their lack of CD3, 19,
and 56 expression, respectively. The percentage of CD34
expression during expansion ranged from 30 to 100%, thus
increasing the likelihood of reprogramming more of an early
lineage cell type (n=9, data not shown). Second, samples were
taken from the purified populations during expansion at different
timepoints as they lost CD34 expression to determine their
receptiveness to reprogramming. A decrease in reprogramming
efficiency was observed in correlation with decreasing percentages
of CD34 expression across populations of cells from four
independent donors (Figure 5A). For example, donor 3096
exhibited only 1 iPSC per 1610
5 input cells when beginning
from cells expanded for 13 days (31% CD34+) compared to 91.5
iPSCs per 1610
5 cells following 3 days when levels of CD34
expression were much higher, 98% (Figure 5B). Third, popula-
tions depleted of CD34+ cells were tested for their ability to
reprogram in parallel with their CD34+ cell counterparts. These
CD34-depleted populations were not receptive to reprogramming
as the CD34+ cells even when the same media and transfection
conditions were used (n=3, Figure 5B). Finally, a side-by-side
comparison of reprogramming efficiency was performed between
unpurified PBMCs and CD34+ cells isolated from 10 different
donors. A medium described previously for the expansion of
erythroblasts and for successful reprogramming studies was used to
ensure media would not be a limiting factor for reprogramming
the PBMCs in our protocol [22,31]. Reprogramming trials
beginning from either PBMCs or CD34+ cells were launched in
Table 1. Diversity across the set of donors used for
reprogramming trials to generate iPSCs.
Donor ID Ethnicity Gender Age
GG Caucasian M 39
A2389 Caucasian M 47
401 Caucasian M 40–60
405 Caucasian M 40–60
482 Caucasian M 40–60
603 Caucasian M 40–60
2317 Caucasian M 29
2341 Hispanic M 30
2364 Caucasian M 29
2369 Caucasian M 27
2447 Caucasian F 50
2583 African A. M 51
2668 African A. M 34
2726 African A. M 38
2849 African A. M 29
2939 Asian F 32
2970 Asian M 29
3002 Asian F 25
3013 Caucasian M 48
3052 Caucasian M 21
3096 African A. M 32
3098 Caucasian F 22
3185 African A. M 42
3233 Asian M 22
3264 African A. F 33
3323 Caucasian F 35
3350 Caucasian M 47
3373 African A. F 47
3389 Caucasian M 22
3415 African A. F 32
3428 Caucasian F 24
3436 African/Native A. F 39
3447 Hispanic F 34
3500 Caucasian M 39
3663 Caucasian F 50
3665 African A. F 25
3675 Hispanic F 42
The ethnicity, gender, and age of all of the donors providing non-mobilized,
whole blood for the reprogramming trials. Blood was collected from all of the
donors, except GG and A2389, using standard blood drawing procedures.
Donors GG and A2389 underwent leukapheresis to provide PBMCs. African A.
indicates African American; M, male; F, female. A range rather than a specific
age was provided for donors 401, 405, 482, and 603.
doi:10.1371/journal.pone.0027956.t001
Transgene-Free iPSCs from Routine Blood Collection
PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e27956parallel using their respective media for expansion. The efficiency
of reprogramming was approximately 2 to 8 fold higher when
beginning with cells purified for CD34 expression in 9 out of the
10 donors compared to those from PBMCs (p=0.007; Figure 6). A
significant fraction of the PBMC population was comprised of
lymphocytes (,79+/214% CD3/CD19) at the time of transfec-
tion (data not shown); therefore, PCR was performed to screen for
potential IgH and TCR gene rearrangements to determine
whether both protocols promoted the generation of iPSCs free
of gene rearrangements. Interestingly, screened clones from either
cell type were free of IgH and TCR gene rearrangements
indicating that both protocols favor the reprogramming of early
progenitor cells. The lower efficiency of reprogramming from the
PBMC population may reflect the dilution of early progenitor
blood cells by a predominately lymphocytic population.
Generation of iPSCs from CD34+ cells using completely
defined reagents
Additional reprogramming trials were performed using com-
pletely defined conditions to enable the production of clinic-grade
iPSCs. A large pool of CD34+ cells mixed from multiple donors
was used for multiple tests and resulted in a successful expansion of
113+/211 fold in defined media compared to 83+/232 fold for
cells in standard conditions after 6 days of expansion (Figure 7A).
Despite the 30-fold difference between the two conditions, the
absolute number of CD34+ cells is similar between the two
populations when multiplied by the percentage of the population
expressing CD34 by flow cytometry. For example, 42+/213% of
the population expanded in standard conditions expressed CD34
and 26+/216% expressed CD34 using completely defined
conditions (Figure 7A). There were no detectable CD3+,
CD19+, or CD56+ cells after 6 days in culture consistent with
our earlier expansion trials (data not shown). The media used for
reprogramming is completely defined with the exception of the
supplement B27 which contains bovine serum albumin (BSA).
However reprogramming was still achieved in the presence or
absence of B27 (Figure 7B). These improvements coupled with a
defined matrix enables the production of iPSCs in a completely
defined process.
Discussion
CD34+ cells possess characteristics that make them an ideal
blood cell to reprogram: they are readily identified, highly
Table 2. Optimizing reprogramming from a range of blood volumes across multiple donors.
Volume of blood (ml) Donor iPSCs/ml of blood iPSCs/16105 cells
Set 1
(N)
Set 2
(N)
.16 3428 0.1 1.9 1 1
.16 2939 0.3 3.8 3 1
.16 3323 0.4 1.4 1
.16 2369 0.9 2.9 1 1
.16 2364 0.1 0.7 1*
.16 3415 1.2 6.6 1 1
8 3052 0.8 8.9 2*
8 3233 0.4 9.4 2*
8 3373 0.1 2.4 1
8 2583 0.5 1.7 4*
8 2970 0.3 1.6 5*
8 3185 0.5 4.5 1*
The table represents reprogramming efficiencies following optimization trials that began with a set of donors providing different volumes of blood. ‘‘iPSCs per ml
blood’’ represents the number of total iPSCs as determined by their ability to stain positively for Tra1-81 expression and exhibit characteristic, ES-like morphology
divided by the volume of blood processed from the donor. ‘‘iPSCs per 1610
5’’ cells represents the number of total iPSCs divided by the total number of cells used for
each transfection after 6 days of expansion multiplied by 1610
5 cells. Set 1 refers to plasmid combination Set 1 expressing C-myc and Set 2 refers to the triple plasmid
combination set using expressing L-myc. Asterisks indicate the generation of iPSCs from CD34+ cells isolated fresh from blood while all other trials were performed from
CD34+ cells isolated from PBMCs that were frozen down immediately after isolation from blood. N indicates the number of independent reprogramming trials
performed for each donor. Reprogramming efficiencies were averaged where N.1.
doi:10.1371/journal.pone.0027956.t002
Table 3. Improved reprogramming across multiple donors
from a single vial of blood.
Donor iPSCs/ml of blood iPSCs/16105 cells
Set 1
(N)
Set 2
(N)
3002 4.5 24.7 2*
3350 2 3.1 2*
2317 7.4 59.3 4
2668 6 55.2 1
3013 3.8 50 1
3500 4.6 55.2 2
603 10.6 77.3 1
482 12 19.2 1
405 1.3 5 1
401 10.5 8.4 1
The table represents reprogramming trials beginning from a single vial of blood
performed across a set of donors independent from Table 2. Set 1 refers to the
two plasmid combination expressing C-myc and Set 2 involves the 3 plasmid
combination set expressing L-myc. Asterisks indicate the generation of iPSCs
from CD34+ cells isolated fresh from blood while all other trials were performed
from CD34+ cells isolated from PBMCs that were frozen down immediately after
isolation from blood. N indicates the number of single vial reprogramming trials
performed for each donor. Reprogramming efficiencies were averaged where
N.1.
doi:10.1371/journal.pone.0027956.t003
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characteristic of more differentiated cell types. However, their low
numbers in circulating blood have made them a less desirable cell
type for reprogramming because large volumes of blood were
predicted to be required for the generation of iPSCs. We describe
a method to generate insert-free iPSCs from CD34+ cells
beginning from a single vial of blood or less. In some cases, the
number of CD34+ cells that expanded exceeded that required for
a single transfection after 6 days in culture making it possible to
transfect after only 3 days of expansion, shorter than the amount
of time Chou and colleagues used to reprogram unpurified
PBMCs [22].
Proliferation contributes to reprogramming efficiency; therefore,
choosing a culture medium that promotes proliferation will effectively
promote reprogramming. Data presented in our manuscript supports
this assertion because all four donor populations examined were
almost 100% positive for CD34 expression after 3 days in culture, but
they were not equally receptive to reprogramming (Figure 5A). Cells
from donor 3096 demonstrated the highest fold expansion following
purification as well as the highest efficiency of reprogramming.
However, we go on to demonstrate that proliferation is not the only
contributor to efficient reprogramming. In our experiments, the
purity of the cell population diminishes over time following
purification, but the cells within the culture continue to expand
despite low CD34 expression. Figure 1C shows that this expanding
population 10 days following purification consists primarily of early
lineage progenitor cells. This result indicates that our medium has the
capacity to stimulate the proliferation of non-T and non-B cells that
have never been or are no longer CD34+. If proliferation were the
primary force driving the efficiency of reprogramming, then it would
be expected that proliferating non-T/non-B cells within our
population would be equally receptive to reprogramming regardless
of their time in culture. Our results are contrary to this hypothesis,
however, because the efficiency of reprogramming decreases as the
magnitude of CD34 expression decreases. This is observed across
four independent donor cell populations and is consistent with
dependence of reprogramming on CD34 expression (see Figure 5A).
These results, taken together, support our hypothesis that both
proliferation and cell identity contribute to the efficiency of
reprogramming.
We have also outlined a protocol that begins to systematically
address some of the challenges in the generation of clinical-grade
iPSCs in an effort to advance their use from research lab to clinic.
iPSCs must not only be manufactured consistently from a tractable
tissue source but also satisfy safety requirements. The core of these
requirements includes the use of completely defined culture
conditions and a standardized reprogramming method that results
in the removal of the potentially oncogenic transgenes employed to
reprogram the cells. The starting point of the protocol is the actual
patient sample, a single vial of blood. The ability to begin from
frozen rather than fresh starting material allows flexibility to
launch multiple reprogramming trials in parallel. We demonstrate
that either CD34+ cells or PBMCs may be used as the source
population for reprogramming. The iPSCs generated by this
method are free of transfected DNA as well as B and T cell gene
rearrangements. Several challenges remain, however, before
routine production of clinical-grade iPSCs can be completely
performed. First, there is considerable variation in the efficiency of
reprogramming from donor to donor. Some of this variation is
likely due to the inherent differences among the donors, but a
careful examination of external sources of variation at each step
from blood to iPSCs may well reveal areas in addition to those we
have uncovered that can be better controlled. For example, we
demonstrate potential in the ability to produce iPSCs using
completely defined reagents to minimize variation. Second, an
automated method for screening and selecting iPSCs during
reprogramming would facilitate high throughput production of
iPSCs. Third, a robust production protocol must also include a
method for the rapid screening of iPSCs to identify those that both
lack potentially harmful mutations and are readily differentiated
into various cell types. In sum, the generation of iPSCs using a
standardized process beginning from early progenitor cells isolated
from routine blood draws minimizes this variation and is a good
starting point to provide a more comparable baseline for analysis.
We present the first steps towards a standardized process to make
the generation of clinical-grade iPSCs a reality.
Materials and Methods
Ethics Statement
All human primary cells were generated in vitro from tissue
samples from human donors with appropriate written informed
consent given to the commercial providers.
All animal work was conducted according to relevant national
and international guidelines under the approval of the Cellular
Dynamics International Animal Care and Use Committee. As a
private company, our animal facility does not provide a permit
number or approval ID since mouse is not a protected species.
Table 4. The efficiency of reprogramming CD34+ cells beginning from 4 ml of blood or less.
Donor Half Vial Quarter Vial
iPSCs/ml blood iPSCs/16105 cells N iPSCs/ml blood iPSCs/16105 cells N
3500* 1.3 8.3 2 10.0 178.5 2
3052 2.7 31.5 2 0 0 1
401 10.0 6.6 1 4.5 4.9 2
405 3.0 8.8 1 1.8 13.5 2
603 0.5 4.1 1 0.3 10.0 1
482 3.0 37.3 1 0 0 1
Single, 8 ml vials of blood were fractionated from a subset of the donors from Table 3 to represent half or one-quarter of a whole vial. PBMCs were isolated and CD34+
cells purified from them for use in the reprogramming method described here. Asterisks indicate the generation of iPSCs from CD34+ cells isolated fresh from blood
while all other trials were performed from CD34+ cells isolated from PBMCs that were frozen down immediately after isolation. Plasmid combination Set 2 expressing L-
myc was used for transfection on cells from each of these donors. N indicates the number of independent reprogramming trials performed. Reprogramming efficiencies
were averaged where N.1.
doi:10.1371/journal.pone.0027956.t004
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Peripheral (PB.1 and PB.2) and cord (CB.1 and CB.2) blood-
derived CD34+ cells were obtained from AllCells (Emeryville, CA
USA). Blood collections were performed at AllCells and Meriter
Laboratories (Madison, WI USA) using standard, 8 ml Vacutainer
Cell Processing Tubes (both sodium citrate and sodium heparin-
based tubes are acceptable; BD Biosciences; Franklin Lakes, NJ
USA). Appropriate documentation for informed consent was
completed prior to blood collection (Meriter Laboratories).
Vacutainers were processed within 24 hours of collection. Briefly,
the PBMC-containing upper phase was collected and washed with
ice-cold PBS (Invitrogen; Carlsbad, CA USA). Cells were either
frozen down or used directly for purification with the CD34
MicroBead Kit (Miltenyi; Auburn, CA USA) and used according
to the manufacturer’s protocol. Some samples were treated with
Histopaque (Sigma Aldrich; St. Louis, MO USA) to minimize the
number of red blood cells (RBCs) and centrifuged at 2000 rpm for
20 minutes without braking. The interface containing the PBMCs
was removed if samples were treated with histopaque, cells washed
again with chilled PBS, centrifuged at 6006gf o r1 5m i n u t e sa n d
either frozen down with CryoStor10 (StemCell Technologies;
Vancouver, BC Canada) or used directly for purification. CD34+
cell expansion media: StemSpan SFEM (StemCell Technologies),
Flt3, SCF, TPO each at a final concentration of 300 ng/ml, IL-6
(100 ng/ml) and IL-3 (10 ng/ml) (Peprotech; Rocky Hill, NJ USA),
supplemented with DNaseI (final concentration at 20 U/ml), and 16
Antibiotic-antimycotic (Invitrogen) for overnight recovery. Defined
expansion media: serum-free StemSpan H3000 (StemCell Technol-
ogies), animal-free IL-6 (R&D Systems Minneapolis, MN USA), and
recombinant human IL-3, TPO, Flt3, and SCF (Peprotech) at the
same concentrations listed above. PBMC expansion media: Stem-
Span SFEM, ExCyte Medium Supplement (Millipore; Billerica,
MA), Glutamax (Invitrogen), SCF (250 ng/ml), IL-3 (20 ng/ml),
Erythropoietin (2 U/ml;Prospec; Rehovot, Israel), IGF-1 (40 ng/ml;
Prospec), and Dexamethasone (1 mM; Fisher; Waltham, MA).
PBMCs were resuspended at 1610
6 cells/ml for expansion.
Flow cytometry
Cell surface staining of hematopoietic cells was performed with
CD45-PE, CD34-APC, CD19-APC and CD56-PE (BD Biosci-
ences) and CD3-PE (eBioscience; San Diego, CA USA) antibodies.
iPSCs were processed directly for antibody staining for the
presence of Tra-1-81 (Stemgent; Cambridge, MA USA) and
SSEA-4 (BD Pharmingen; San Diego, CA USA). Propidium
Iodide (Sigma Aldrich) was added for dead cell exclusion, and all
stained cells were analyzed in combination with their respective
isotype controls using a flow cytometer (Accuri; Ann Arbor, MI
USA).
Table 5. Characterization of insert-free iPS clones derived from fresh blood.
Passage Number
Donor Clone No.
Tra1-81
live stain IgH/TCR Loss of oriP
Endogenous
Expression
Integration
Free Karyotype Teratomas
% Tra1-
81+ % SSEA-4+
3002 1 + 7 n/a 7 7 6 7 85.6 81.2
4 + 7 n/a 7 7 6 7 90.2 81.0
2939 4 + 11 9 18 18 11, 13 9 82.0 84.0
5 + 12 10 18 18 8, 11 10 86.3 86.3
2970 6 + 18 18 24 24 3, 25 8 84.1 90.8
3389 4 + 10 9 10 10 12
5 + 10 9 10 10 12
6 + 10 9 10 10 12
1 + n/a 9
2 + n/a 9
3 + n/a 9
3233 4.2-2 + n/a 9
1.1-1 + 10 9
1.4-4 + 10 9
4.2-1 + 10 9
3185 3.3 + 10 7
3052 5 + 3n / a
6 + 3n / a
3500 11 + 3n / a
12 + 3n / a
This table represents the passage numbers at which further characterization of a subset of the iPSCs generated across different blood donors were examined. All clones
positively stained for the pluripotency marker Tra-1-81. The clones were free of detectable IgH and TCR gene rearrangements (IgH/TCR). A subset of these clones were
also screened by PCR using multiple primer sets for loss of the transfected, oriP/EBNA1 DNA including those for EBNA1. The numbers indicate the passage where
amplified products are no longer detected (Loss of oriP). The expression of endogenous genes was verified by RT-PCR and included DNMT3B, REX1, TERT, UTF1, Oct4,
Sox2, Nanog, Lin28, Klf4, and C-myc (Endogenous Expression). Clones were deemed free of integrated DNA by PCR using primers specific for segments of the
transfected DNA encoding Oct4, Sox2, Nanog, Lin28, Klf4, and C-myc (Integration Free). Genetic integrity of the clones was confirmed by cytogenetic analysis at one or
more passages where indicated. Teratomas were generated by injecting iPSCs at the indicated passage number into immunodeficient mice. Clones were also assessed
by flow cytometry using antibodies specific for cell surface expression of both Tra-1-81 and S SEA-4. n/a indicates tests not performed with the indicated clone. All
clones satisfied our minimal criteria for an iPSC by exhibiting a classic ES-like morphology and stained positively for Tra-1-81 and AP.
doi:10.1371/journal.pone.0027956.t005
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The CD34 nucleofection kit and device (Lonza; Allendale, NJ
USA) were used for transfections. For CD34+ cells, 3.5 mg of each
plasmid in Combination Set 1 and 3 ug of each plasmid for
Combination Set 2 except for the L-myc containing plasmid where
2 mg was transfected using program U-08. Cells were seeded onto
RetroNectin-coated 6-well plates (Takara Bio, Inc; Otsu, Shiga
Japan). Seeding density ranged from 5610
4 to 1610
5 cells/ml.
Reprogramming media: StemSpan SFEM (StemCell Technologies)
supplemented with non-essential amino acids (NEAA; Invitrogen),
0.56 Glutamax, N2B27 (Invitrogen), 0.1 mM b-mercaptoethanol
(Sigma-Aldrich), 100 ng/mL zebrafish basic fibroblast growth
factor (zbFGF), 0.5 mM PD0325901, 3 mM CHIR99021, 0.5 mM
A-83-01 (all molecules from Stemgent), and 10 mM HA-100 (Santa
Cruz; Santa CruzCA USA). Conditions for PBMCreprogramming
relied on 1610
6 cells per transfection, program T-16, and DNA
Figure 4. Characterization of iPSCs derived from CD34+ blood cells. A subset of iPSC clones were characterized for pluripotency. The
experiments demonstrated in this figure provide representative examples of the types of results observed for characterization studies using iPS
clones 4 and/or 5 derived from donors 2939 and 3389. A. Cytogenetic analysis on G-banded metaphase cells from iPS clone 4 exhibiting a normal
karyotype. B and C. RT-PCR confirms the endogenous expression of classic pluripotency genes and the absence of expression from transgenes. A
standard in-house iPS line served as the positive control k. D. Clones were deemed free of episomal (E) DNA and genomic integration (G) by PCR. E.
PCR was used to track the loss of oriP/EBNA1-based plasmids at multiple passages using primers that amplify EBNA1. A control plasmid at 1 and 20
copies per genome was used to establish the sensitivity of the PCR at 1 copy per 3,000 cells. F. PCR screen using primers specific for the joining region
and all three of the conserved framework regions (FR1, FR2 and FR3) to amplify immunoglobulin heavy chain (IgH) gene rearrangements and two
assays with primers specific to the T cell receptor (TCR) gamma gene rearrangement. G. Representative image of donor 2939 clone 5 differentiated in
vitro into neurons (i). Clone 5 also demonstrated differentiation into all three germ layers: ii) epithelium iii) endoderm iv) mesoderm v) ectoderm vi)
endoderm from teratomas formed when iPSCs were injected into immunodeficient, SCID mice.
doi:10.1371/journal.pone.0027956.g004
Figure 5. The presence of CD34+ cells correlates with reprogramming efficiency. A. CD34+ cells from four different blood donors were
expanded for 3, 6, 9, or 13 days. A large volume of blood was collected from donors 3096, 2849, and 3389 to ensure sufficient cell numbers to
perform these studies. Expanding CD34+ cells using plasmid DNA combination Set 2. The efficiency of reprogramming was calculated as the total
number of iPSCs exhibiting morphological features characteristic of an ES cell and an ability to stain positively for Tra-1-81 divided by the total
number of cells used for transfection. Black Squares depict the percentage of the population expressing CD34 at the indicated days of expansion. B.
Representative reprogramming trial whereby both the positive (i) and negative (ii) fraction following purification were used for reprogramming. Panel
(i) shows one well of a 6-well plate that contains successfully reprogrammed colonies from donor 2939 based on their ability to demonstrate AP
activity. The CD34-depleted fraction from donor 2939 was unable to form colonies as indicated by the lack of AP staining when performed in parallel
with the purified population panel, ii. Panels iii and iv magnify the colony in panel (i) marked by a white arrowhead and demonstrates expression of
Tra-1-81 (green), panel iv.
doi:10.1371/journal.pone.0027956.g005
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cells. Reprogramming media for PBMCs was the same with the
exception of the small molecule cocktail which contained
recombinant human LiF (Millipore), 3 uM CHIR99021, and
0.5 uM A-83-01. In general, cultures were fed with fresh medium
every other day for 9 to 14 days then transitioned to TeSR2 (Stem
Cell Technologies) without the addition of small molecules. iPSC
colonies were scored with Tra-1-81 antibody (StainAlive
TM
DyLight
TM 488 Mouse anti-Human Tra-1-81 antibody; Stemgent)
or mouse-anti-Tra-1-60 IgM antibody (R&D) in combination with
goat anti-mouse IgM Alexa 488 (Invitrogen), and alkaline
phosphatase expression (Vector Blue Alkaline Phosphatase Sub-
strate Kit III, Vector Laboratories; Burlingame, CA USA).
Detecting endogenous expression of pluripotency
markers
Total RNA was isolated using the RNeasy Mini Plus kit
(Qiagen; Valencia, CA USA) per the manufacturer’s protocol.
Approximately 1 mg of total RNA was used for cDNA synthesis
using the SuperScript III First-Strand Synthesis system for RT-
PCR (Invitrogen). RT-PCR was performed using previously
described primers and those listed in Table 6 [2]. cDNA was
Figure 6. Comparing the efficiency of reprogramming between PBMCs and CD34+ cells. PBMCs and CD34+ cells were isolated from single
tubes of blood provided from 10 different donors. The efficiency of reprogramming following transfection with DNA Combination Set 2 was
determined for each donor and each method. ‘‘Total colonies’’ refers to all iPS colonies derived from either CD34+ or PBMC populations that stain
positively for Tra1-60 and ‘‘iPS-like’’ colonies are those that stain positively for Tra1-60, exhibit clear iPS morphology, and are large enough to pick for
expansion. Input cells refer to the number of CD34+ cells or PBMCs were used for transfection. The efficiencies across all donors from both methods
were compared using the Wilcoxon signed rank test (two-sided), p=0.007.
doi:10.1371/journal.pone.0027956.g006
Figure 7. The generation of iPSCs from blood using completely defined conditions. A. Fold expansion of CD34+ cells pooled from multiple
blood donors in standard (n=13) and completely defined conditions (n=2) after 6 days of expansion. Fold expansion was calculated from the total
number of cells at day 6 divided by the number of cells the day after purification. Percentages indicate the fraction of cells expressing CD34 in the
total population as assessed by flow cytometry. B. Reprogramming trials were performed on CD34+ cells obtained by leukapheresis from donors GG
and A2389 with and without the B27 supplement.
doi:10.1371/journal.pone.0027956.g007
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Master Mix (Promega; Madison, WI USA).
Episomal and Genomic DNA isolation
Episomal DNA was isolated as previously described and
genomic DNA was procured using the QIAamp DNA Blood
Mini Kit (Qiagen) according to the manufacturer’s protocol [2].
PCR was performed on 140 ng of genomic DNA and 50 ng of
episomal DNA using GoTaq Green Master mix. Plasmid DNA
was used as a control and diluted to 1 and 0.1 copies per genome.
Immunoglobulin heavy chain and T cell gene
rearrangements
Both T cell gene segment rearrangements as well as immuno-
globulin gene (IgH) rearrangements were screened using the T
Cell Receptor Gamma Gene Rearrangement and IgH Rear-
rangement Assay kits for Gel Detection respectively (Invivoscribe;
San Diego, CA USA). A subset of iPSCs from either CD34+ cells
and PBMCs were screened using the T Cell Receptor Gamma
Gene clonality, T cell Receptor Beta Gene Clonality, IgH and IgK
B cell clonality Assay kits for ABI fluorescence detection
(InvivoScribe).
Karyotyping
G-banding analysis was performed by Cell Line Genetics
(Madison, WI).
In Vitro Differentiation and Teratoma Studies
iPSC clones from donor 2939 (clones 4 and 5) were
differentiated at passage 15 into neurons according to protocols
from previously published methods [32,33]. Cells were fixed with
4% formaldehyde, washed, and permeabilized using 0.1% Triton-
X-100 and 1% Normal Donkey Serum in PBS. Cells were
incubated with MAP2 (Sigma M1406, 1:3000) or Tuj1 (Sigma
T8660, 1:5000) antibodies for 2 hours at room temperature,
washed, and incubated with A488-conjugated secondary antibod-
ies (Invitrogen, A21121 for MAP2, A21202 for TUJ1). DNA was
stained using Hoechst 33342. Teratomas - iPSCs grown on MEFs
were harvested using collagenase IV (Invitrogen) and injected into
hind limb muscles of 6-week old female SCID/beige mice (Harlan
Laboratories; Indianapolis, IN USA). Each mouse was injected
with one, confluent 6-well plate of cells and a total of 3 mice were
injected per cell line. Tumors were embedded in paraffin and
sectioned; sections were processed with hematoxylin and eosin
staining at the UWCCC Histology Lab at the University of
Wisconsin-Madison. Unstained sections were processed with
nestin and alpha-feto protein antibodies by the Immunohisto-
chemical Core Service affiliated with the Department of Surgery
at the University of Wisconsin-Madison. All animal work was
conducted according to relevant national and international
guidelines under the approval of the Cellular Dynamics Interna-
tional Animal Care and Use Committee.
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